-+ 0.00%
-+ 0.00%
-+ 0.00%

Tvardi Therapeutics Completes Enrollment For Lead Program In Phase 2 Clinical Trial Of TTI-101 For Patients With Idiopathic Pulmonary Fibrosis

Benzinga·05/27/2025 12:06:32
Listen to the news

Topline data from the REVERT IPF trial anticipated in 4Q 2025

Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that it has completed enrollment for its lead program in a Phase 2 clinical trial of TTI-101 for patients with idiopathic pulmonary fibrosis (IPF). The REVERT IPF Phase 2 clinical trial is a randomized, double-blind, placebo-controlled clinical trial of TTI-101 in patients suffering from IPF. Key endpoints include safety and lung function (FVC).

TTI-101, is an oral, small molecule inhibitor of STAT3. STAT3 is a central mediator across critical fibrotic signaling pathways that drive uncontrolled deposition, proliferation, survival and immune suppression.